• Test Code:
  • Department:
  • Test Synonyms:
    Hepatitis C genotype HCV genotype
  • CPT Code(s):

Hepatitis C (HCV) infection is the most common chronic blood-borne infection in the United States with an estimated seroprevalence of 1.6%.  An estimated 3.2 million Americans suffer from chronic HCV infection and an estimated 85% of those with acute hepatitis C progress to chronic infection, of which 20%-25% will develop complications such as cirrhosis within 2 to 3 decades of onset.  In addition to the quantitation of HCV RNA by polymerase chain reaction (PCR) to measure active viremia in antibody-positive chronic HCV infected patients,  genotype identification of Hepatitis C is important for physicians tailor dose and duration of pegylated interferon – α and ribavirin combination therapy.


The Abbott RealTime HCV Genotype II RUO has been validated in our laboratory for clinical use.  This assay detects the major HCV genotypes 1a, 1b, 2, 3, 4, 5, and 6 through the use of genotype-specific fluorescent-labeled oligonucleotide probes.

Specimen Requirements:

  • 5-10 mL of blood in purple (EDTA) tube.  Specimen must be centrifuged and separated within 6 hours. 
  • Freeze plasma for transport to lab. 
  • Alternatively, serum from a red top or SST tube may be separated, frozen, and submitted for the assay.
  • Pediatric Minimum is 200µL of plasma or serum.

A REQUISITION FORM MUST ACCOMPANY ALL SAMPLES.  Please include detailed clinical information.

Test Performed (Days):


Turn Around Time:

7-10 days

Shipment Sensitivity Requirements:

Package and ship specimen on dry ice.  Ship via overnight express, using the FedEx priority overnight label provided.  Contact Client Services for shipping kits and instructions at (855) 535-1522.


Abbott RealTime HCV Genotype II RUO © 2010 Abbott Molecular, Inc. Des Plaines, Illinois, USA.

Additional Info:

Clinical Utility:
Guidelines and product information for the current FDA-approved pegylated interferon support the determination of HCV genotypes as an independent predictor of sustained virologic response following pegylated interferon – α and ribavirin combination therapy.  This test is intended to aid physicians in the management of HCV-infected individuals undergoing anti-viral therapy.   

The Hepatitis C viral load of the sample being tested must be above 320 IU/mL.

The Knight Cancer Institute at Oregon Health & Science University is a pioneer in the field of precision cancer medicine. The institute's director, Brian Druker, M.D., helped prove it was possible to shut down just the cells that enable cancer to grow. This breakthrough has made once-fatal forms of the disease manageable and transformed how cancer is treated. The OHSU Knight Cancer Institute is the only National Cancer Institute-designated Cancer Center between Sacramento and Seattle – an honor earned only by the nation's top cancer centers. It is headquarters for one of the National Cancer Institute's largest research collaboratives, SWOG, in addition to offering the latest treatments and technologies as well as hundreds of research studies and clinical trials.

Learn More